Scholarlink

Background <p>Bladder cancer (BLC) is one of the most common malignancies of the urinary system and represents a major public health burden. Myeloid cells are key components of the tumor microenvironment and play critical roles in tumor progression and therapeutic response; however, their prognostic significance in BLC remains incompletely understood.</p> Methods <p>The prognostic value of individual myeloid cell markers was evaluated using immunohistochemistry and survival analyses. A myeloid-based prognostic model was constructed using least absolute shrinkage and selection operator (LASSO) regression. The model was validated across multiple independent cohorts. Multiplex immunofluorescence staining and RNA sequencing were performed to investigate immune landscape alterations and signaling pathways associated with different risk groups.</p> Results <p>High CD68 expression within tumor regions was associated with favorable prognosis, whereas elevated expression of CD14, CD74, CD163, and S100A12 correlated with poor survival outcomes in BLC patients. A myeloid risk score (MRS) was subsequently established and demonstrated robust prognostic performance across validation cohorts. Transcriptomic analysis revealed significant activation of the PI3K–AKT signaling pathway in the MRS-high group. Furthermore, MRS-high tumors exhibited increased expression of PD-L1, FOXP3, and CD11b, along with reduced CD8⁺ T-cell infiltration, indicating a highly immunosuppressive tumor microenvironment. Potential therapeutic targets and candidate agents for MRS-high patients were also identified.</p> Conclusions <p>We developed a robust myeloid cell–based prognostic model that effectively stratifies BLC patients by risk and reveals distinct immunosuppressive mechanisms in high-risk tumors. This model may facilitate personalized prognostic assessment and guide precision therapeutic strategies for patients with bladder cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrative analysis of myeloid cell signatures identifies a prognostic risk model and potential mechanisms in bladder cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Yuhang Wang,
  • Siyuan Gong,
  • Jia Shen,
  • Guangyuan Liu,
  • Minfeng Chen

摘要

Background

Bladder cancer (BLC) is one of the most common malignancies of the urinary system and represents a major public health burden. Myeloid cells are key components of the tumor microenvironment and play critical roles in tumor progression and therapeutic response; however, their prognostic significance in BLC remains incompletely understood.

Methods

The prognostic value of individual myeloid cell markers was evaluated using immunohistochemistry and survival analyses. A myeloid-based prognostic model was constructed using least absolute shrinkage and selection operator (LASSO) regression. The model was validated across multiple independent cohorts. Multiplex immunofluorescence staining and RNA sequencing were performed to investigate immune landscape alterations and signaling pathways associated with different risk groups.

Results

High CD68 expression within tumor regions was associated with favorable prognosis, whereas elevated expression of CD14, CD74, CD163, and S100A12 correlated with poor survival outcomes in BLC patients. A myeloid risk score (MRS) was subsequently established and demonstrated robust prognostic performance across validation cohorts. Transcriptomic analysis revealed significant activation of the PI3K–AKT signaling pathway in the MRS-high group. Furthermore, MRS-high tumors exhibited increased expression of PD-L1, FOXP3, and CD11b, along with reduced CD8⁺ T-cell infiltration, indicating a highly immunosuppressive tumor microenvironment. Potential therapeutic targets and candidate agents for MRS-high patients were also identified.

Conclusions

We developed a robust myeloid cell–based prognostic model that effectively stratifies BLC patients by risk and reveals distinct immunosuppressive mechanisms in high-risk tumors. This model may facilitate personalized prognostic assessment and guide precision therapeutic strategies for patients with bladder cancer.